Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and {up triangle, open}9-THC

European Journal of Pharmacology

Volumn 572, Issue 1, 2007, Pages 32-39

  Araya, Katherine A ^a   David Pessoa Mahana, C ^a   González, Luis G ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

AM 251; Cannabinoid; Na+,K+ ATPase; Naloxone; Receptor; WIN55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CANNABINOID; CANNABINOID 1 RECEPTOR; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NALOXONE; OPIATE PEPTIDE; OUABAIN; PERTUSSIS TOXIN; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BENZOXAZINE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; NARCOTIC ANTAGONIST; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; INCUBATION TIME; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SYNAPTOSOME; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; ENZYMOLOGY; FEMALE; IN VITRO STUDY; METABOLISM; PHYSIOLOGY;

ANIMALS; BENZOXAZINES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MICE; MORPHOLINES; NALOXONE; NAPHTHALENES; NARCOTIC ANTAGONISTS; OUABAIN; PERTUSSIS TOXIN; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SODIUM-POTASSIUM-EXCHANGING ATPASE; SYNAPTOSOMES; TETRAHYDROCANNABINOL;

EID: 34548536880     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.013     Document Type: Article

References (49)

1. +-ATPase. Clin. Exp. Hypertens. 20 (1998) 465-480
2. +-ATPase: heterogeneity in structure, diversity in function. Am. J. Physiol. 275 (1998) F633-F650
3. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312 Pt 2 (1995) 637-641
4. Breivogel C.S., and Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 5 (1998) 417-431
5. Breivogel C.S., and Childers S.R. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther. 295 (2000) 328-336
6. Breivogel C.S., Walker J.M., Huang S.M., Roy M.B., and Childers S.R. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 47 (2004) 81-91
7. Busch L., Sterin-Borda L., and Borda E. Expression and biological effects of CB1 cannabinoid receptor in rat parotid gland. Biochem. Pharmacol. 68 (2004) 1767-1774
8. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci. 78 (2006) 549-563
9. Devane W.A., Spain J.W., Coscia C.J., and Howlett A.C. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J. Neurochem. 46 (1986) 1929-1935
10. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., and Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48 (1996) 567-592
11. Fiske C.H., and Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66 (1925) 375-400
12. Freissmuth M., Waldhoer M., Bofill-Cardona E., and Nanoff C. G protein antagonists. Trends Pharmacol. Sci. 20 (1999) 237-245
13. Gardner E.L., and Lowinson J.H. Marijuana's interaction with brain reward systems: update 1991. Pharmacol. Biochem. Behav. 40 (1991) 571-580
14. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., and Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61 (1997) PL 191-PL 197
15. Glass M., and Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17 (1997) 5327-5333
16. Gonzalez L.G., Portillo E., Del Pozo E., and Baeyens J.M. Changes in [3H]glibenclamide binding to mouse forebrain membranes during morphine tolerance. Eur. J. Pharmacol. 418 (2001) 29-37
17. +-adenosine triphosphatase activity in frog spinal cord membrane fractions. Neurosci. Lett. 59 (1985) 291-295
18. +-ATPase using in vitro and in vivo studies. Eur. J. Pharmacol. 458 (2003) 291-297
19. +-ATPase in renal proximal tubules via the cAMP pathway. Eur. J. Pharmacol. 321 (1997) 259-263
20. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
21. Mackie K., Lai Y., Westenbroek R., and Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15 (1995) 6552-6561
22. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-294
23. +-ATPase. Brain Res. 957 (2002) 311-319
24. +-ATPase in morphine-induced antinociception. J. Pharmacol. Exp. Ther. 306 (2003) 1122-1128
25. Milligan G. Mechanisms of multifunctional signalling by G protein-linked receptors. Trends Pharmacol. Sci. 14 (1993) 239-244
26. Nagy A., and Delgado-Escueta A.V. Rapid preparation of synaptosomes from mammalian brain using nontoxic isoosmotic gradient material (Percoll). J. Neurochem. 43 (1984) 1114-1123
27. +-ATPase activity in synergism with neuropeptide Y. Diabetologia 39 (1996) 199-205
28. +-ATPase by serotonin: identification of participating receptors. Neurochem. Res. 24 (1999) 643-649
29. Pontieri F.E., Monnazzi P., Scontrini A., Buttarelli F.R., and Patacchioli F.R. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur. J. Pharmacol. 421 (2001) R1-R3
30. Prather P.L., Martin N.A., Breivogel C.S., and Childers S.R. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol. 57 (2000) 1000-1010
31. Pugh Jr. G., Mason Jr. D.J., Combs V., and Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 281 (1997) 730-737
32. Reche I., Fuentes J.A., and Ruiz-Gayo M. Potentiation of Δ9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and k{cyrillic}-opioid receptors. Eur. J. Pharmacol. 318 (1996) 11-16
33. + pump in cultured guinea pig airway smooth muscle cells by serotonin. J. Pharmacol. Exp. Ther. 293 (2000) 107-112
34. Sadrzadeh S.M., Vincenzi F.F., and Hinds T.R. Simultaneous measurement of multiple membrane ATPases in microtiter plates. J. Pharmacol. Toxicol. Methods 30 (1993) 103-110
35. Selley D.E., Stark S., Sim L.J., and Childers S.R. Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59 (1996) 659-668
36. Shapira M., Gafni M., and Sarne Y. Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res. 806 (1998) 26-35
37. Shen M., and Thayer S.A. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783 (1998) 77-84
38. Sim L.J., Selley D.E., and Childers S.R. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7242-7246
39. Sim L.J., Selley D.E., Xiao R., and Childers S.R. Differences in G-protein activation by mu-and delta-opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307 (1996) 97-105
40. +-ATPase: structure, function, and interactions with drugs. Adv. Neurol. 44 (1986) 681-693
41. Steffens M., Engler C., Zentner J., and Feuerstein T.J. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br. J. Pharmacol. 141 (2004) 1193-1203
42. +-ATPase. Neurochem. Int. 44 (2004) 529-538
43. 1 opioid receptor mechanism. Science 276 (1997) 2048-2050
44. Therien A.G., and Blostein R. Mechanisms of sodium pump regulation. Am. J. Physiol., Cell Physiol. 279 (2000) C541-C566
45. Wang H.Y., Undie A.S., and Friedman E. Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol. Pharmacol. 48 (1995) 988-994
46. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend. 45 (1997) 39-45
47. Welch S.P., Thomas C., and Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272 (1995) 310-321
48. Welch S.P., Huffman J.W., and Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 286 (1998) 1301-1308
49. +-ATPase activity in murine LTK-cells. Mol. Pharmacol. 49 (1996) 373-378